Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2005 May;13(2):111-26.
doi: 10.1037/1064-1297.13.2.111.

Transdermal Methylphenidate, Behavioral, and Combined Treatment for Children With ADHD

Affiliations
Clinical Trial

Transdermal Methylphenidate, Behavioral, and Combined Treatment for Children With ADHD

William E Pelham et al. Exp Clin Psychopharmacol. .

Abstract

Stimulant medication and behavioral treatments are evidence-based for children with attention-deficit/hyperactivity disorder, but the combination of the 2 treatments has been understudied. In this investigation, methylphenidate (MPH) was crossed with 2 levels of behavior modification (BMOD) in a summer treatment program. Twenty-seven children with attention-deficit/hyperactivity disorder, aged 6-12, participated. Children received placebo and 3 doses of transdermal MPH (12.5 cm(2), 25.0 cm(2), and 37.5 cm(2)). BMOD was implemented on alternating weeks. Both treatments produced large and significant effects. Combined treatment was superior to either treatment alone. The effects of transdermal MPH were comparable to those found in this setting in previous studies with multiple stimulant medications and formulations. Consistent with other research, low doses of MPH--even lower than in previous studies--yielded enhanced effects in combination with behavior modification.

Similar articles

See all similar articles

Cited by 38 articles

See all "Cited by" articles

Publication types

MeSH terms

Substances

Feedback